28 June 2023 - Founder and President Steve Pearson to transition to advisor role at beginning of 2024; long-time EVP ...
21 June 2023 - ICER’s third annual “Barriers to Fair Access” report will be published in November 2023. ...
8 June 2023 - Paying for health care is a challenge for many Americans, but the House of Representatives is on ...
5 June 2023 - Proposed updates reflect experience with current framework, benchmarking with other health technology assessment groups, and external stakeholder ...
1 June 2023 - The drugs may force reform to Medicaid. ...
25 May 2023 - Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net ...
15 May 2023 - Report will be subject of Midwest CEPAC meeting in December 2023; draft scoping document open to ...
19 April 2023 - White bagging, brown bagging, and site of service policies developed by payers can reduce significant markup costs ...
18 April 2023 - For decades, many US authors of cost effectiveness analyses referenced a common benchmark or threshold—$50 000 per quality-adjusted ...
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...
3 April 2023 - In late March, the House Committee on Energy and Commerce advanced H.R. 485 - Protecting Health ...
13 April 2023 - Current evidence suggests that resmetirom would achieve common thresholds for cost effectiveness if priced between $39,600–$50,100 per ...
12 April 2023 - Public comment period now open until 9 May 2023; Requests to make oral comment during public ...
12 April 2023 - ICER will evaluate whether multiple formularies offered by the five largest US commercial payers, state health exchange ...
11 April 2023 - Annual unsupported price increase report to be published on December 12. ...